According to our (Global Info Research) latest study, the global Hemoderivative market size was valued at US$ 9646 million in 2024 and is forecast to a readjusted size of USD 14630 million by 2031 with a CAGR of 6.3% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Hemoderivatives, also known as blood-derived products, are therapeutic or diagnostic substances obtained from human or animal blood, primarily from plasma. Through industrial-scale fractionation, valuable proteins such as albumin, immunoglobulins, and coagulation factors are isolated for clinical use. These products are essential in treating a variety of conditions, including immune deficiencies, hemophilia, and surgical bleeding. Due to their biological origin, hemoderivatives are subject to strict regulations to ensure viral safety, traceability, and consistent quality. They play a vital role in modern medicine, especially in intensive care, transfusion therapy, and rare disease management.
The Human Bloodm Albumin market is driven by the increasing prevalence of liver diseases, nephrotic syndrome, and hypoalbuminemia, which require albumin-based therapies. Additionally, Human Bloodm Albumin is widely used in critical care settings for treating burns, shock, and surgical recovery, boosting its demand. The expanding applications of albumin in biopharmaceuticals, including drug delivery, vaccine formulation, and regenerative medicine, further fuel market growth. Rising healthcare expenditures, improvements in plasma collection infrastructure, and growing demand in emerging markets like China and India contribute to the industry's expansion.
However, the market faces challenges such as limited plasma supply and high production costs, as Human Bloodm Albumin is primarily derived from human plasma, which is subject to stringent donation regulations. Stringent government policies and safety concerns regarding pathogen transmission also hinder market growth. Additionally, competition from synthetic and recombinant Human Bloodm Albumin is increasing, though high production costs and market acceptance remain barriers. Overcoming supply chain constraints and advancing rHSA technologies will be crucial for sustaining growth in the global Human Bloodm Albumin market.
The key global producers of Human Bloodm Albumin are Grifols, CSL, Takeda, Octapharma, CBPO, Hualan Bio, Kedrion, and Shanghai RAAS, with the top four manufacturers together holding 60% of the market share. The largest producer is CSL with a market share of 21.25%. In terms of consumption level, the market is mainly distributed in North America, Europe and Asia Pacific, with Asia Pacific having the highest market share of 68.63%.
This report is a detailed and comprehensive analysis for global Hemoderivative market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Hemoderivative market size and forecasts, in consumption value ($ Million), sales quantity (MT), and average selling prices (US$/Kg), 2020-2031
Global Hemoderivative market size and forecasts by region and country, in consumption value ($ Million), sales quantity (MT), and average selling prices (US$/Kg), 2020-2031
Global Hemoderivative market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (MT), and average selling prices (US$/Kg), 2020-2031
Global Hemoderivative market shares of main players, shipments in revenue ($ Million), sales quantity (MT), and ASP (US$/Kg), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Hemoderivative
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Hemoderivative market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Grifols, CSL, Takeda, Octapharma, CBPO, Hualan Bio, Kedrion, Shanghai RAAS, LFB Group, Weiguang Bio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Hemoderivative market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Albumin
Immunoglobulins
Coagulation Factors
Others
Market segment by Application
Therapeutics
Excipient
Other
Major players covered
Grifols
CSL
Takeda
Octapharma
CBPO
Hualan Bio
Kedrion
Shanghai RAAS
LFB Group
Weiguang Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hemoderivative product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Hemoderivative, with price, sales quantity, revenue, and global market share of Hemoderivative from 2020 to 2025.
Chapter 3, the Hemoderivative competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hemoderivative breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Hemoderivative market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Hemoderivative.
Chapter 14 and 15, to describe Hemoderivative sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Hemoderivative. Industry analysis & Market Report on Hemoderivative is a syndicated market report, published as Global Hemoderivative Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031. It is complete Research Study and Industry Analysis of Hemoderivative market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.